Glucose Fresenius Kabi France

Glucose Fresenius Kabi France is an intravenous solution for injection that contains glucose as the sole active ingredient. The product is supplied in a sterile liquid form and is intended for use under medical supervision. It is marketed in the European Union and requires a prescription (Rx). This preparation provides an immediate source of energy for patients who need rapid glucose supplementation.

Glucose Fresenius Kabi France is used in clinical settings where rapid glucose delivery is required. It supports patients who cannot obtain adequate glucose orally or need supplemental energy during medical procedures.

- Treatment of hypoglycemia in emergency or peri‑operative situations. - Component of parenteral nutrition regimens for patients unable to eat. - Energy supplementation during major surgery or critical care. - Support for patients with metabolic disorders requiring controlled glucose infusion. - Temporary glucose source during fasting periods before diagnostic tests.

Glucose Fresenius Kabi France may cause a range of reactions, most of which are related to the infusion of a carbohydrate solution.

Common: - Mild hyperglycemia or transient increase in blood glucose levels. - Local irritation or pain at the infusion site. - Nausea or mild gastrointestinal discomfort. - Headache or dizziness during rapid infusion. - Mild electrolyte shifts, such as decreased potassium.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic reactions, including rash, itching, or anaphylaxis. - Fluid overload or pulmonary edema in patients with compromised cardiac function. - Severe electrolyte disturbances, such as hyponatremia. - Metabolic acidosis in patients with impaired metabolism.

When using Glucose Fresenius Kabi France, clinicians should consider several safety factors to minimize risks.

- Assess blood glucose levels before and during infusion, especially in diabetic patients. - Monitor fluid balance and cardiac status to avoid overload. - Adjust infusion rate in patients with renal or hepatic impairment. - Use caution in patients with known hypersensitivity to glucose solutions. - Ensure proper aseptic technique to prevent infection at the injection site. - Verify compatibility with other intravenous medications before co‑administration.

Glucose Fresenius Kabi France can interact with other agents, influencing its safety and efficacy.

Avoid: - Concurrent administration of high‑dose insulin without close glucose monitoring. - Co‑infusion with hypertonic solutions that may exacerbate electrolyte imbalances. - Use with medications that cause severe hypoglycemia, such as sulfonylureas, without monitoring.

Use with caution: - Concurrent use of diuretics that may affect fluid and electrolyte status. - Administration alongside catecholamines, which can raise blood glucose levels. - Co‑administration with glucocorticoids, which may increase glucose requirements. - Use with other parenteral nutrition components; verify compatibility and total caloric load.